ArticleAdvanced materials (Deerfield Beach, Fla.)2026
Microneedle Delivery of Small Extracellular Vesicles From Young Blood to Treat Endothelial Senescence.
Article in Advanced materials (Deerfield Beach, Fla.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Adipose Tissue to Cardiac Repair: Extracellular Vesicles in Cardiovascular Regeneration.Journal of cellular and molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Circulating extracellular vesicles (EVs) play a crucial role in mediating communication between different cell populations and organs, significantly influencing inflammation and vascular diseases. To evaluate the role of EVs in regulating senescence, small EVs isolated from umbilical cord plasma (young sEVs, Y-sEVs) are compared with those from the plasma of elderly individuals (old sEVs, O-sEVs, >70 years old) to identify key cargo components. To investigate their effects on senescence, Y-sEVs or O-sEVs are administered to aged mice using transdermal microneedle patches, enabling sustained EV release into the circulation. Doxorubicin is administered to induce enhanced endothelial senescence in aged mice (22-24 months old). Single-cell RNA sequencing revealed that Y-sEV treatment downregulated senescence-related genes in endothelial cells decreased the proportion of activated fibroblasts in the heart, and reduced disease-associated microglia in the brain. Delivery of Y-sEVs via microneedle patches preserved endothelial cell function, and mitigated inflammation and senescence, whereas O-sEVs exacerbated endothelial dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.